文献速递甲状腺疾病

甲巯咪唑治疗与急性胰腺炎风险:一项基于人群的队列研究

Methimazole Treatment and Risk of Acute Pancreatitis: A Population-based Cohort Study.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该研究基于2013—2018年行政健康数据库回顾性分析,识别23087例甲巯咪唑新使用者,其中61例住院。甲巯咪唑使用者治疗前三个三分期急性胰腺炎风险升高(RR 3.40、2.40、2.80),此后消失;18个月内绝对风险在所有性别和年龄组均低于0.4%。结果支持欧洲药品管理局警告,但风险增加似乎仅限于治疗最初数月。

要点

  • 甲巯咪唑治疗前三个三分期急性胰腺炎风险升高,RR分别为3.40、2.40、2.80
  • 风险增加在治疗前三个三分期后消失
  • 18个月内急性胰腺炎绝对风险在所有性别和年龄组均低于0.4%

核心结论

  • 结果支持欧洲药品管理局(EMA)警告,提示甲巯咪唑使用与急性胰腺炎风险增加相关。
  • 但这种增加似乎仅限于甲巯咪唑治疗最初数月。
  • 就绝对值而言,患者发生急性胰腺炎的概率低,远低于1%。

研究设计与样本

  • 回顾性分析行政健康数据库(2013—2018年),数据来自居民登记处、医院出院记录(ICD-9-CM 577.0)和药品索赔登记处(ATC H03BB02)。
  • 识别23087例甲巯咪唑新使用者,其中61例住院发生在研究期间。
  • 评估甲巯咪唑使用者18个月治疗内的急性胰腺炎风险,按三分期分层。
  • 采用泊松回归估计年龄和性别调整的率比(RR)及相对95%置信区间(CI),比较甲巯咪唑使用者与非使用者的急性胰腺炎发生率。
  • 计算甲巯咪唑使用者急性胰腺炎的绝对风险。

主要发现

  • 甲巯咪唑治疗前三个三分期急性胰腺炎风险升高:第一个三分期RR 3.40(95% CI: 2.12-5.48),第二个三分期RR 2.40(95% CI: 1.36-4.23),第三个三分期RR 2.80(95% CI: 1.66-4.73)。
  • 此后风险增加消失。
  • 甲巯咪唑使用者治疗前18个月内急性胰腺炎绝对风险在所有性别和年龄组均低于0.4%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: A warning has been recently issued by the European Medicine Agency (EMA) regarding a potential increased risk of acute pancreatitis (AP) in methimazole (MMI) users. OBJECTIVE: To investigate the association between MMI and the diagnosis of AP in a population-based study. MATERIALS AND METHODS: A retrospective analysis of administrative health databases was conducted (2013-2018). Relevant data were obtained from: (1) inhabitants registry, (2) hospital discharge records (ICD-9-CM 577.0), and (3) drug claims registry (ATC H03BB02). We evaluated AP risk in MMI users in 18 months of treatment, stratifying results by trimester. Poisson regression was used to estimate the age- and sex-adjusted rate ratios (RR), and the relative 95% confidence intervals (CI), comparing rates of AP between MMI users and nonusers. The absolute risk of AP in MMI users was also calculated. RESULTS: A total of 23 087 new users of MMI were identified. Among them, 61 hospitalizations occurred during the study period. An increase in AP risk was evident during the first 3 trimesters of therapy (RR 3.40 [95% CI: 2.12-5.48]; RR 2.40 [95% CI: 1.36-4.23]; RR 2.80 [95% CI: 1.66-4.73]), but disappeared thereafter. The AP absolute risk in MMI users during the first 18 months of treatment was less than 0.4% in all sex and age classes. CONCLUSIONS: Our results support the EMA warning, suggesting an increased risk of AP associated with MMI use. However, such an increase seems limited to the first months of MMI treatment. Moreover, in absolute terms, the probability of AP is low among patients, well below 1%.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Pecere A, Caputo M, Sarro A, et al. Methimazole Treatment and Risk of Acute Pancreatitis: A Population-based Cohort Study. J Clin Endocrinol Metab. 2020. PMID: 32813014. doi:10.1210/clinem/dgaa544

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。